文献速递乳腺癌支持与姑息治疗

接受帕妥珠单抗治疗的HER2阳性乳腺癌患者腹泻的发生率与管理

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
PubMed 文献 · Ann Oncol · 2017-01-01

该分析基于CLEOPATRA、NeoSphere和TRYPHAENA三项研究,共1443例HER2阳性乳腺癌患者,评估含帕妥珠单抗方案腹泻的发生率与严重程度。含帕妥珠单抗方案全级别腹泻发生率为28%至72%,主要为低级别,多发生在首个含帕妥珠单抗周期,因腹泻导致的剂量延迟或停药不常见。

要点

  • 含帕妥珠单抗方案全级别腹泻发生率为28%至72%,以1-2级为主。
  • 腹泻发生率在首个含帕妥珠单抗周期最高,后续周期下降。
  • 因腹泻导致剂量延迟或停药的比例为0%至8%,总体可管理。

核心结论

  • 在转移性和早期乳腺癌中,含帕妥珠单抗方案相关腹泻常见但可管理,多为低级别且多发生于首个治疗周期,因腹泻导致的药物延迟或停药不常见。

研究设计与样本

  • 基于CLEOPATRA(n=804,转移性乳腺癌)、NeoSphere(n=416,早期乳腺癌)和TRYPHAENA(n=223,早期乳腺癌)三项研究,共1443例患者,按实际接受的治疗分析腹泻发生率与严重程度,并评估腹泻同期发热性中性粒细胞减少及既存胃肠道合并症的影响,亚组分析采用CLEOPATRA数据。

主要发现

  • 各研究中含帕妥珠单抗方案全级别腹泻发生率一般为28%至72%(1级21%至54%;2级8%至37%;3级0%至12%;4级0%)。
  • 腹泻发生率在首个含帕妥珠单抗周期最高,后续周期下降。
  • 因腹泻导致剂量延迟或停药的比例为0%至8%。
  • 在帕妥珠单抗治疗且发生腹泻的患者中,47%至67%接受了药物干预,最常用为洛哌丁胺。
  • 腹泻与发热性中性粒细胞减少的重叠不常见,范围为0%至11%;未观察到既存胃肠道合并症与腹泻之间的关系。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pertuzumab disrupts heterodimerization between human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), HER3, and HER4. Thus, pertuzumab could result in adverse events similar to those observed with EGFR antagonists, such as diarrhea. We report the incidence and severity of diarrhea observed with pertuzumab in the CLEOPATRA, NeoSphere, and TRYPHAENA studies. PATIENTS AND METHODS: Patients (n = 1443) had metastatic [CLEOPATRA (n = 804)] or early-stage breast cancer [NeoSphere (n = 416) and TRYPHAENA (n = 223)]. The incidence and severity of diarrhea were analyzed by treatment received. The incidence of febrile neutropenia concurrent with diarrhea and the effect of pre-existing gastrointestinal comorbidities were also evaluated. Subgroup analyses were carried out using CLEOPATRA data. RESULTS: The incidence of all-grade diarrhea across studies was generally greater for pertuzumab-based treatment, ranging from 28% to 72% (grade 1, 21%-54%; grade 2, 8%-37%; grade 3, 0%-12%; grade 4, 0%). Incidence was highest during the first pertuzumab-containing cycle, decreasing with subsequent cycles. Dose delays or discontinuations due to diarrhea were infrequent, ranging from 0% to 8%. Among pertuzumab-treated patients with diarrhea, 47%-67% received pharmacological intervention, most commonly with loperamide. Overlap between diarrhea and febrile neutropenia was uncommon, ranging from 0% to 11%. No relationship was observed between pre-existing gastrointestinal comorbidities and diarrhea. In CLEOPATRA, patients ≥65 years treated with pertuzumab had a higher incidence of grade 3 diarrhea than patients <65 years (19% versus 8%). All-grade diarrhea occurred at greater frequency among pertuzumab-treated Asian versus white patients with metastatic breast cancer (74% versus 63%); the corresponding rates in the control arm were 53% and 45%, respectively. CONCLUSIONS: In both the metastatic and early-stage breast cancer settings, diarrhea was common but manageable for all pertuzumab-containing regimens. Diarrheal episodes were mainly low grade and occurred most often during the first treatment cycle. Diarrheal-related drug delays or discontinuations were uncommon. CLINICALTRIALS.GOV IDENTIFIERS: NCT00567190 (CLEOPATRA), NCT00545688 (NeoSphere), NCT00976989 (TRYPHAENA).

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Swain SM, Schneeweiss A, Gianni L, et al. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Ann Oncol. 2017. PMID: 28057664. doi:10.1093/annonc/mdw695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。